{"id":60519,"date":"2024-12-19T07:02:28","date_gmt":"2024-12-19T06:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/"},"modified":"2024-12-19T07:02:28","modified_gmt":"2024-12-19T06:02:28","slug":"fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/","title":{"rendered":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"},"content":{"rendered":"
\n

MIAMI–(BUSINESS WIRE)–Xcovery Holdings, Inc.<\/a>, an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in providing a new first line option for patients with ALK-positive NSCLC.<\/p>\n

<\/a>
<\/a><\/p>\n

\nEnsartinib is an ALK tyrosine kinase inhibitor (TKI) designed to improve outcomes for patients with ALK-positive NSCLC. The FDA approval is based on data from the pivotal global Phase III eXalt3 clinical trial, in which ensartinib demonstrated statistically significant improvements in progression-free survival (PFS) over crizotinib.<\/p>\n

\n\u201cThe approval of Ensartinib by FDA brings another new medicine to patients battling ALK-positive NSCLC, expanding the options to optimize treatment in the first-line setting. This result could not have been achieved without the dedication of our team members and the support of patients, physicians, and all stakeholders involved in the clinical development of Ensartinib,\u201d said Giovanni Selvaggi, Chief Medical Officer of Xcovery.<\/p>\n

\n\u201cFDA approval of Ensartinib represents a significant milestone in Xcovery\u2019s mission to advance precision medicine for patients with cancer,\u201d said Kevin Sang, CEO of Xcovery. \u201cIn addition to Ensartinib, we are continuing our efforts in developing more pipeline targeted drugs for patients worldwide.\u201d<\/p>\n

\nAbout Ensartinib<\/b><\/p>\n

\nEnsartinib is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals. It is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC.<\/p>\n

\nAbout Xcovery<\/b><\/p>\n

\nXcovery is a pharmaceutical company working to improve the lives of patients with cancer by discovering and developing small molecules that precisely target cancer growth mechanisms. Xcovery is developing a pipeline of drugs targeting a wide range of advanced solid tumors with a focus on lung cancer.<\/p>\n

\nForward\u2010Looking Statements<\/b><\/p>\n

\nThis press release contains forward\u2010looking statements that are based on company management\u2019s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
Kevin Sang
\n
Chief Executive Officer
\n
(561) 835-9356
\n
kevin.sang@xcovery.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MIAMI–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in providing a new … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60519","6":"format-standard","7":"category-industry"},"yoast_head":"\nFDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MIAMI–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in providing a new ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-19T06:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\",\"datePublished\":\"2024-12-19T06:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/\"},\"wordCount\":371,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241218355621\\\/en\\\/2336501\\\/22\\\/smalXcovery_PMS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/\",\"name\":\"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241218355621\\\/en\\\/2336501\\\/22\\\/smalXcovery_PMS.jpg\",\"datePublished\":\"2024-12-19T06:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241218355621\\\/en\\\/2336501\\\/22\\\/smalXcovery_PMS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241218355621\\\/en\\\/2336501\\\/22\\\/smalXcovery_PMS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend","og_description":"MIAMI–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in providing a new ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/","og_site_name":"Pharma Trend","article_published_time":"2024-12-19T06:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","datePublished":"2024-12-19T06:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/"},"wordCount":371,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/","url":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/","name":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg","datePublished":"2024-12-19T06:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241218355621\/en\/2336501\/22\/smalXcovery_PMS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60519"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60519\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}